NCT06350318View on ClinicalTrials.gov

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Follicular LymphomaMarginal Zone LymphomaB-Cell Lymphoma
Interventions
DRUG

Zanubrutinib

Zanubrutinib is an anti-cancer medication administered orally.

DRUG

Rituximab

Rituximab is a biologic medication administered intravenously or subcutaneously.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

BeiGene
All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER